SCHEMBL18943211

SCHEMBL18943211

O=CC1CC(F)(F)C(=O)N1I

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18614168 1.00 NOTUM (0.30) NOTUM
SCHEMBL15587106 0.76 PTGER4 (0.34) NOTUM
SCHEMBL22025479 0.74 PTGER4 (0.31) —
SCHEMBL17808005 0.73 PTGER4 (0.38) —
SCHEMBL22024924 0.72 NOTUM (0.33) NOTUM
SCHEMBL22025629 0.71 NOTUM (0.32) NOTUM
SCHEMBL18943749 0.71 NOTUM (0.32) NOTUM
SCHEMBL18943079 0.71 APLNR (0.31) —
SCHEMBL16058266 0.63 PTGER4 (0.64) —
SCHEMBL18943066 0.62 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3176162-A1 DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2017-06-07 — — EP disclosed
EP-3175852-A1 DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS Cayman Chemical Company, Incorporated (US) 2017-06-07 — — EP disclosed
Send feedback